Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14799397 | 1.00 | ITGB1 (1.00) | ITGB1ITGA4 | |
| Trifluoroacetic Acid SCHEMBL14799358 | 0.95 | ITGB1 (0.91) | ITGB1ITGA4 | |
| SCHEMBL20387801 | 0.91 | ITGB1 (0.83) | ITGB1ITGA4 | |
| SCHEMBL14799323 | 0.91 | ITGB1 (0.83) | ITGB1ITGA4 | |
| SCHEMBL6625626 | 0.91 | ITGB1 (0.83) | ITGB1ITGA4 | |
| SCHEMBL6628051 | 0.89 | ITGB1 (0.84) | ITGB1ITGA4 | |
| SCHEMBL20045967 | 0.89 | ITGB1 (0.84) | ITGB1ITGA4 | |
| SCHEMBL6627822 | 0.89 | ITGB1 (1.00) | ITGB1ITGA4 | |
| SCHEMBL7552133 | 0.87 | ITGB1 (0.81) | ITGB1ITGA4 | |
| SCHEMBL6626685 | 0.87 | ITGB1 (1.00) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491178-B2 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery | HOFFMANN-LA ROCHE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-104039356-B | For chitosan targeted delivery and that small molecule integrin antagonist is covalently attached | 弗·哈夫曼-拉罗切有限公司 | 2018-08-17 | — | — | CN | disclosed |
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE, INC. | 2018-04-12 | — | — | US | disclosed |
| EP-2806896-B1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN LA ROCHE (CH) | 2018-01-03 | — | — | EP | disclosed |
| EP-2806897-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING LFA-1 | HOFFMANN LA ROCHE (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9650363-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1 | HOFFMANN-LA ROCHE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650363-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1 | HOFFMANN-LA ROCHE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20130197205-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | HOFFMANN-LA ROCHE INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | ARROWHEAD RESEARCH CORPORATION (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | ARROWHEAD RESEARCH CORPORATION (US) | 2013-03-28 | — | — | US | disclosed |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | CHEN LI (US) | 2004-10-21 | — | — | US | disclosed |
| US-6806365-B2 | ACTIVITY AS INHIBITORS OF BINDING BETWEEN VCAM-1 AND CELLS EXPRESSING VLA-4. SUCH COMPOUNDS ARE USEFUL FOR TREATING DISEASES WHOSE SYMPTOMS AND/OR DAMAGE ARE RELATED TO THE BINDING OF VCAM-1 TO CELLS EXPRESSING VLA-4. | HOFFMANN-LA ROCHER INC. | 2004-10-19 | — | — | US | disclosed |
| EP-1005446-B1 | N-AROYLPHENYLALANINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-02-25 | — | — | EP | disclosed |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | CHEN LI (US) | 2003-06-12 | — | — | US | disclosed |
| US-6455550-B1 | INHIBITORS OF BINDING BETWEEN VASCULAR CELL ADHESION MOLECULES AND CELLS EXPRESSING VLA-4 INTEGRIN; ANTIINFLAMMATORY AGENTS | HOFFMANN-LA ROCHE INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099005-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGB4 | ITGB1 1/4885ITGA4 2/4885 |
| US-20030109459-A1 | N-alkanoylphenylalamine derivatives | VCAM1, ICAM1, SELL | ITGB1 14/4885ITGA4 9/4885 |
| US-20130197205-A1 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY | ITGB1, ITGA4, ITGA1 | ITGB1 1/4885ITGA4 2/4885 |
| US-20040210051-A1 | N-alkanoylphenylalanine derivatives | VCAM1, ICAM1, CD59 | ITGB1 12/4885ITGA4 10/4885 |
| US-11491178-B2 | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery | ITGB1, ITGA4, ITGB4 | ITGB1 1/4885ITGA4 2/4885 |
| US-20130079383-A1 | Lipid Compounds Targeting VLA-4 | LPAR4, ASGR1, VCAM1 | ITGB1 20/4885ITGA4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.